• SN-38, FUBP1, and FUSE: What the Study Shows

  2026-10-07

  A 2017 Biochemical Pharmacology study identified camptothecin and SN-38 as inhibitors of the interaction between the transcriptional regulator FUBP1 and its single-stranded DNA target, FUSE. The findings extend the mechanistic interpretation of topoisomerase I drugs by linking their activity to transcriptional regulation, while remaining limited to biochemical screening and cell-based evidence.

• ML385 and NRF2: Reading Ferroptosis Evidence

  2026-10-07

  ML385 is an NRF2 inhibitor that can help researchers test whether antioxidant signaling contributes to ferroptosis and alcoholic liver injury. This evidence-focused guide explains what the Poria cocos study shows, what it does not prove, and how the compound supports stronger mechanistic interpretation.

• How Mtb Uses BMX to Control Lysosomal Acidification

  2026-10-06

  A 2026 Nature Communications study identifies a host–pathogen mechanism in which Mycobacterium tuberculosis uses the secreted protein Chp2 to promote BMX-dependent phosphorylation of ATP6V1E1, weakening V-ATPase assembly and lysosomal acidification. The findings connect host kinase signaling to phagosome maturation and support further investigation of BMX as a possible host-directed therapeutic target, while remaining subject to model-specific and translational limitations.

• Brassinolide: Research Context and Evidence

  2026-10-06

  Brassinolide is a plant brassinosteroid studied as a growth-regulating hormone and as a reference compound for structure–activity research. This overview compares findings from rice and bean bioassays, explains what supplier-reported cancer and diabetes results can—and cannot—establish, and defines important evidence and applicability limits.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-10-05

  A 2026 MedComm study identifies NAT1 as a metabolic–immune regulator that connects ENO1 acetylation and lactate production with TRAF6-dependent PD-L1 stabilization in colorectal cancer. Its integrated patient, multi-omics, cellular, and mouse-model evidence suggests that the NAT1–ENO1–lactate axis may influence responses to immune checkpoint blockade, while remaining preclinical.

• Leptin (116-130), Amide, Mouse: Evidence Overview

  2026-10-05

  Leptin (116-130), amide, mouse is a research peptide fragment marketed as a tool for studying leptin biology, but the supplied evidence does not establish that this fragment reproduces full-length leptin activity. This overview separates established leptin physiology, supplier claims, conceptual applications, and the limitations of extrapolating from unrelated inflammatory and cardiovascular research.

• ApexPrep DNA Plasmid Miniprep Kit in AML Research

  2026-10-04

  The ApexPrep DNA Plasmid Miniprep Kit is described as a membrane-based alkaline lysis system for obtaining molecular biology grade plasmid DNA from bacterial cultures. In AML research, that product role should be separated from the peer-reviewed evidence linking the LMO2–LDB1 complex to leukemia-cell growth and survival.

• AP20187: Evidence, Applications, and Limits

  2026-10-03

  AP20187 is a chemical inducer of dimerization used with engineered fusion proteins to create conditional control over selected signaling pathways. This overview separates supplier-described applications from findings in a peer-reviewed mouse study of hypoxia-associated pain, emphasizing evidence strength, translational boundaries, and unanswered research questions.

• TAK-715: A Dephosphorylation-Aware Assay Guide

  2026-10-02

  TAK-715 is a selective p38 MAPK inhibitor for dissecting inflammatory signaling from kinase activation to cytokine output. This guide translates recent structural insights into practical assay decisions without assuming that every p38α inhibitor produces the same biochemical or cellular response.

• JWH 133 and CB2R in Liver Iron Overload

  2026-10-01

  JWH 133 is a selective CB2R agonist studied in a preclinical model of iron overload-related liver injury. The reference study links CB2R activation with lower hepatic iron deposition, reduced oxidative stress, and coordinated STAT3/hepcidin and Nrf2/FPN1 signaling.

• Poria cocos, NRF2, and Ferroptosis in ALD

  2026-10-01

  Zhou and colleagues show that Poria cocos polysaccharides protect against alcoholic liver disease by strengthening NRF2-associated antioxidant responses and reducing ferroptosis-related iron and lipid damage. The study combines alcohol-exposed rats, an in vitro injury model, ferrostatin-1, and ML385 to connect oxidative stress, inflammation, and iron-dependent cell death in a mechanistic framework.

• β-NMN Workflows for Metabolic Research

  2026-09-30

  Build controlled NAD+ manipulation studies with β-NMN, from glucose-stimulated insulin secretion assays to diabetic cardiac-fibrosis models. This practical guide connects dosing, endpoint selection, and mechanistic validation while separating product-informed parameters from study-specific optimization.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-09-30

  The reference study positions moesin as both a circulating indicator of sepsis severity and a mechanistic participant in endothelial barrier failure. By combining patient measurements, LPS and cecal ligation and puncture models, and HMEC perturbation experiments, it connects serum moesin with SOFA scores, pulmonary injury, Rock1/MLC signaling, NF-κB activation, and vascular hyperpermeability.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-09-29

  Use the Annexin V-FITC/PI Apoptosis Assay Kit to separate viable, early apoptotic, and late apoptotic or necrotic cells in a rapid dual-fluorescence workflow. Its value is especially clear in neuroinflammation and stem-cell rescue studies, where stage-specific cell-death data can complement pathway and behavioral readouts.

• SN-38 Disrupts FUBP1–FUSE DNA Binding

  2026-09-29

  A 2017 Biochemical Pharmacology study identified camptothecin and SN-38 as inhibitors of the FUBP1–FUSE DNA interaction, adding a transcriptional mechanism to their established topoisomerase I activity. The work connects SN-38 with FUBP1-dependent gene regulation in hepatocellular carcinoma and provides a testable framework for studying this pathway in other tumor models.

8195 records 1/547 page Next 12345 下5页 Last page